SGN LIV1A

Drug Profile

SGN LIV1A

Alternative Names: SGN-LIV1A

Latest Information Update: 01 Jan 2017

Price : $50

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 10 Dec 2016 Interim efficacy and safety data from a phase I trial in Breast cancer released by Seattle Genetics
  • 16 Apr 2016 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 09 Feb 2016 Phase-I clinical trials in Breast cancer (Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top